Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$33.99
pos +0.67
+2.00%
Today's Range: 33.40 - 34.02 | PFE Avg Daily Volume: 18,949,500
Last Update: 09/30/16 - 12:59 PM EDT
Volume: 11,240,877
YTD Performance: 3.22%
Open: $33.44
Previous Close: $33.32
52 Week Range: $28.25 - $37.39
Oustanding Shares: 6,065,652,424
Market Cap: 206,171,525,892
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 8 9
Moderate Buy 0 0 0 0
Hold 6 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.92 1.92 1.86 1.80
Latest Dividend: 0.30
Latest Dividend Yield: 3.53%
Dividend Ex-Date: 11/08/16
Price Earnings Ratio: 15.31
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
15.31 30.10 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-4.83% 7.41% 15.37%
GROWTH 12 Mo 3 Yr CAGR
Revenue -1.50 -0.20 -0.06
Net Income -23.80 -0.30 -0.10
EPS -21.70 -0.40 -0.17
Earnings for PFE:
EBITDA 18.13B
Revenue 48.85B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $0.63 $0.53 $2.46 $2.64
Number of Analysts 6 5 10 10
High Estimate $0.65 $0.56 $2.48 $2.90
Low Estimate $0.61 $0.51 $2.42 $2.34
Prior Year $0.60 $0.53 $2.20 $2.46
Growth Rate (Year over Year) 4.44% 0.00% 11.73% 7.61%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

Cempra Is Ready to Run Real Money Pro($)

Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.
An update on some recent small biotech recommendations.
These sectors are full of high-priced, low-growth stocks.
Often, pictures speak louder than words.
Zoetis is not averse to a little noise as investors, analysts take notice.
If and when interest rates go up, this basket of stocks should continue to do well.
The leadership is quite stark.
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
Stocks travel a good distance just to end up nowhere.
It was nice to fill in for Doug Kass on what was a very uneventful Monday to begin the week. The market traded in an extremely narrow range for the day, and outside the strength in biotech and the weakness in oil after a nice recent rally there really wasn't much of note that happened today. Still, there were some good conversations on the Daily Dairy despite the directionless market.

Columnist Conversations

We added this one Monday and mentioned it Tuesday right here in CC, we'll take it off the board. SOLD WDC O...
The market is rebounding nicely after yesteday's sell-off.  Biotech has recaptured half of its three perc...
The Federal Reserve has made it relatively clear that they intend to raise interest rates in the December mee...
The iShares NASDAQ Biotechnology ETF (IBB) has been trading for the last two months in a channel delineated by...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.